Hyderabad-Based Pharmaceutical Company Launches Biosimilar Rituximab in India

by Reshma Anand on  August 4, 2015 at 11:45 AM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

Under the brand name "Maball", a drug firm called Hetero has launched biosimilar Rituximab in India. It can be used for the treatment of certain types of cancers and rheumatoid arthritis.
Hyderabad-Based Pharmaceutical Company Launches Biosimilar Rituximab in India
Hyderabad-Based Pharmaceutical Company Launches Biosimilar Rituximab in India

The product "will be marketed and distributed by Hetero Healthcare Ltd, a group company of Hetero", said the firm

Hetero Group CMD Bandi Parthasaradhi Reddy said: "The launch of Maball strengthens Hetero's position in the biosimilar market, and has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (MAB's)."

"Biosimilars is one of the key strategic business areas for Hetero. We have invested in biosimilars and will introduce more biosimilar MAB's in the future. We also have plans to introduce affordable biosimilar Rituximab into key markets outside India through our partners," he added.

"Rituximab is used alone or with other drugs to treat non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. It is also used for the treatment of other indications such as rheumatoid arthritis," said Hetero.

Source: PTI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...